CD38 and cancer: Furthermore, the novel link between MDSCs and up-regulated expression of CD38 and KLRG1 on T cells and NK cells identified in this study suggests a wider scope of applications for CD38- and KLRG1-blocking drugs in immunotherapies of cancers and inflammatory diseases.